Skip to main content

Table 7 Strict OMERACT-OARSI responder analysis

From: Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial

Group

13 Weeks n (%)

26 Weeks n (%)

Synvisc-One

17 (53)

19 (59)

Hydros

21 (66)

22 (69)

Hydros-TA

24 (71)

22 (65)

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us